|
Index | - | P/E | - | EPS (ttm) | -1.59 | Insider Own | 1.16% | Shs Outstand | 30.32M | Perf Week | -9.72% |
Market Cap | 1.17B | Forward P/E | - | EPS next Y | -2.14 | Insider Trans | 0.00% | Shs Float | 19.00M | Perf Month | -15.00% |
Income | -53.80M | PEG | - | EPS next Q | -0.46 | Inst Own | 67.60% | Short Float | 14.29% | Perf Quarter | 56.64% |
Sales | - | P/S | - | EPS this Y | -25.80% | Inst Trans | -8.45% | Short Ratio | 7.82 | Perf Half Y | 53.60% |
Book/sh | 6.08 | P/B | 5.47 | EPS next Y | 41.20% | ROA | - | Target Price | 44.14 | Perf Year | - |
Cash/sh | 5.29 | P/C | 6.29 | EPS next 5Y | - | ROE | - | 52W Range | 18.60 - 40.81 | Perf YTD | -1.71% |
Dividend | - | P/FCF | - | EPS past 5Y | - | ROI | - | 52W High | -18.48% | Beta | - |
Dividend % | - | Quick Ratio | 27.30 | Sales past 5Y | - | Gross Margin | - | 52W Low | 78.87% | ATR | 2.90 |
Employees | 60 | Current Ratio | 27.30 | Sales Q/Q | - | Oper. Margin | - | RSI (14) | 48.42 | Volatility | 8.58% 8.47% |
Optionable | Yes | Debt/Eq | 0.00 | EPS Q/Q | 75.00% | Profit Margin | - | Rel Volume | 0.74 | Prev Close | 33.27 |
Shortable | Yes | LT Debt/Eq | 0.00 | Earnings | Nov 05 AMC | Payout | - | Avg Volume | 347.45K | Price | 33.27 |
Recom | 1.30 | SMA20 | -1.80% | SMA50 | -0.54% | SMA200 | 17.94% | Volume | 0 | Change | 0.00% |
![]() | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
![]() | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||
![]() | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||
![]() | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for treatment of cancers. Its lead product candidate is ORIC-101, a small molecule antagonist of the glucocorticoid receptor, which has been linked to resistance to multiple classes of cancer therapeutics across various solid tumors. The company's second product candidate is ORIC-533, an orally bioavailable small molecule inhibitor of CD73 being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens. It is also developing multiple precision medicines targeting other cancer resistance mechanisms. The company was founded in 2014 and is headquartered in South San Francisco, California. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
![]() | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
![]() |
open in yahoo | open in reuters | open in google |
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features. Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite